MedTrace Logo

Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab

NCT01311232 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2017-10-27

No results posted yet for this study

Summary

This study is a retrospective analysis to identify factors influencing hepatitis B virus reactivation in patients treated with rituximab containing chemotherapy. Rituximab monoclonal antibody targeting CD20 induces B-cell depletion resulting in prolonged immune suppression. This leads to frequent reactivation of patients with a previous history of exposure to HBV or HBV carrier.

We collect the clinical features and laboratory findings of patients satisfied the inclusion criteria as follows.

1. Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) or \\ follicular B-cell lymphoma (FL).
2. Patients who had received at least two cycles of rituximab-CHOP or rituximab-CVP as a primary treatment
3. Patients with a history of previous exposure to HBV

* HBV surface antigen (HBs Ag) positive Or
* HBV core antibody (IgG anti-HBc antibody) positive

Then, we compare the HBV reactivation group with the control group (HBV reactivation does not happen) to find factors influencing HBV reactivation.

Conditions

  • Patients With Diffuse Large B-cell Lymphoma or Follicular Lymphoma
  • Patients Treated With Rituximab-CHOP or Rituximab-CVP

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Eligibility

Min Age
15 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-01
Primary Completion
2012-12-01
Completion
2013-12-01

Countries

  • China
  • Malaysia
  • Singapore
  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01311232 on ClinicalTrials.gov